Virtual  ||| S:0 E:8 ||| JJ
support  ||| S:8 E:16 ||| NN
for  ||| S:16 E:20 ||| IN
paediatric  ||| S:20 E:31 ||| JJ
HIV  ||| S:31 E:35 ||| NNP
treatment  ||| S:35 E:45 ||| NN
decision  ||| S:45 E:54 ||| NN
making  ||| S:54 E:61 ||| VBG
The  ||| S:61 E:65 ||| DT
objective  ||| S:65 E:75 ||| NN
of  ||| S:75 E:78 ||| IN
this  ||| S:78 E:83 ||| DT
study  ||| S:83 E:89 ||| NN
is  ||| S:89 E:92 ||| VBZ
to  ||| S:92 E:95 ||| TO
review  ||| S:95 E:102 ||| VB
clinical  ||| S:102 E:111 ||| JJ
outcomes  ||| S:111 E:120 ||| NNS
of  ||| S:120 E:123 ||| IN
recommendations  ||| S:123 E:139 ||| NNS
made  ||| S:139 E:144 ||| VBN
by  ||| S:144 E:147 ||| IN
a  ||| S:147 E:149 ||| DT
multidisciplinary  ||| S:149 E:167 ||| JJ
paediatric  ||| S:167 E:178 ||| JJ
virtual  ||| S:178 E:186 ||| JJ
clinic  ||| S:186 E:193 ||| NN
( ||| S:193 E:194 ||| -LRB-
PVC ||| S:194 E:197 ||| NNP
)  ||| S:197 E:199 ||| -RRB-
for  ||| S:199 E:203 ||| IN
complex  ||| S:203 E:211 ||| JJ
case  ||| S:211 E:216 ||| NN
management  ||| S:216 E:227 ||| NN
of  ||| S:227 E:230 ||| IN
paediatric  ||| S:230 E:241 ||| JJ
HIV  ||| S:241 E:245 ||| NN
as  ||| S:245 E:248 ||| IN
a  ||| S:248 E:250 ||| DT
model  ||| S:250 E:256 ||| NN
of  ||| S:256 E:259 ||| IN
care  ||| S:259 E:264 ||| NN
within  ||| S:264 E:271 ||| IN
a  ||| S:271 E:273 ||| DT
tertiary  ||| S:273 E:282 ||| JJ
network ||| S:282 E:289 ||| NN
.  ||| S:289 E:291 ||| .
A  ||| S:291 E:293 ||| DT
retrospective  ||| S:293 E:307 ||| JJ
review  ||| S:307 E:314 ||| NN
of  ||| S:314 E:317 ||| IN
the  ||| S:317 E:321 ||| DT
clinical  ||| S:321 E:330 ||| JJ
outcomes  ||| S:330 E:339 ||| NNS
of  ||| S:339 E:342 ||| IN
paediatric  ||| S:342 E:353 ||| NN
and  ||| S:353 E:357 ||| CC
adolescent  ||| S:357 E:368 ||| NNS
( ||| S:368 E:369 ||| -LRB-
0-21  ||| S:369 E:374 ||| CD
years ||| S:374 E:379 ||| NNS
)  ||| S:379 E:381 ||| -RRB-
referrals  ||| S:381 E:391 ||| NNS
to  ||| S:391 E:394 ||| TO
the  ||| S:394 E:398 ||| DT
PVC  ||| S:398 E:402 ||| NNP
at  ||| S:402 E:405 ||| IN
St.  ||| S:405 E:409 ||| NNP
Mary ||| S:409 E:413 ||| NNP
's  ||| S:413 E:416 ||| POS
Hospital ||| S:416 E:424 ||| NNP
,  ||| S:424 E:426 ||| ,
Imperial  ||| S:426 E:435 ||| NNP
College  ||| S:435 E:443 ||| NNP
Healthcare  ||| S:443 E:454 ||| NNP
NHS  ||| S:454 E:458 ||| NNP
Trust ||| S:458 E:463 ||| NNP
,  ||| S:463 E:465 ||| ,
London  ||| S:465 E:472 ||| NNP
was  ||| S:472 E:476 ||| VBD
performed  ||| S:476 E:486 ||| VBN
between  ||| S:486 E:494 ||| IN
October  ||| S:494 E:502 ||| NNP
2009  ||| S:502 E:507 ||| CD
and  ||| S:507 E:511 ||| CC
November  ||| S:511 E:520 ||| NNP
2013.  ||| S:520 E:526 ||| CD
234  ||| S:526 E:530 ||| CD
referrals  ||| S:530 E:540 ||| NNS
were  ||| S:540 E:545 ||| VBD
made  ||| S:545 E:550 ||| VBN
for  ||| S:550 E:554 ||| IN
182  ||| S:554 E:558 ||| CD
children  ||| S:558 E:567 ||| NNS
from  ||| S:567 E:572 ||| IN
37  ||| S:572 E:575 ||| CD
centres ||| S:575 E:582 ||| NN
,  ||| S:582 E:584 ||| ,
discussed  ||| S:584 E:594 ||| VBN
in  ||| S:594 E:597 ||| IN
42  ||| S:597 E:600 ||| CD
meetings  ||| S:600 E:609 ||| NNS
( ||| S:609 E:610 ||| -LRB-
median  ||| S:610 E:617 ||| JJ
age  ||| S:617 E:621 ||| NN
13  ||| S:621 E:624 ||| CD
years ||| S:624 E:629 ||| NNS
,  ||| S:629 E:631 ||| ,
IQR  ||| S:631 E:635 ||| NNP
10-15  ||| S:635 E:641 ||| NNP
years ||| S:641 E:646 ||| NNS
) ||| S:646 E:647 ||| -RRB-
.  ||| S:647 E:649 ||| .
Reasons  ||| S:649 E:657 ||| NNS
for  ||| S:657 E:661 ||| IN
referral  ||| S:661 E:670 ||| NN
included  ||| S:670 E:679 ||| VBD
virological  ||| S:679 E:691 ||| JJ
failure  ||| S:691 E:699 ||| NN
( ||| S:699 E:700 ||| -LRB-
44 ||| S:700 E:702 ||| CD
% ||| S:702 E:703 ||| NN
) ||| S:703 E:704 ||| -RRB-
,  ||| S:704 E:706 ||| ,
simplification  ||| S:706 E:721 ||| NN
of  ||| S:721 E:724 ||| IN
the  ||| S:724 E:728 ||| DT
current  ||| S:728 E:736 ||| JJ
regimen  ||| S:736 E:744 ||| NNS
( ||| S:744 E:745 ||| -LRB-
24 ||| S:745 E:747 ||| CD
% ||| S:747 E:748 ||| NN
)  ||| S:748 E:750 ||| -RRB-
and  ||| S:750 E:754 ||| CC
antiretroviral  ||| S:754 E:769 ||| JJ
drug  ||| S:769 E:774 ||| NN
complications  ||| S:774 E:788 ||| NNS
( ||| S:788 E:789 ||| -LRB-
24 ||| S:789 E:791 ||| CD
% ||| S:791 E:792 ||| NN
) ||| S:792 E:793 ||| -RRB-
.  ||| S:793 E:795 ||| .
At  ||| S:795 E:798 ||| IN
latest  ||| S:798 E:805 ||| JJS
follow-up ||| S:805 E:814 ||| JJ
,  ||| S:814 E:816 ||| ,
PVC  ||| S:816 E:820 ||| NNP
advice  ||| S:820 E:827 ||| NN
had  ||| S:827 E:831 ||| VBD
been  ||| S:831 E:836 ||| VBN
instituted  ||| S:836 E:847 ||| VBN
in  ||| S:847 E:850 ||| IN
80 ||| S:850 E:852 ||| CD
%  ||| S:852 E:854 ||| NN
of  ||| S:854 E:857 ||| IN
referrals ||| S:857 E:866 ||| NNS
.  ||| S:866 E:868 ||| .
Suppression  ||| S:868 E:880 ||| NN
following  ||| S:880 E:890 ||| VBG
virological  ||| S:890 E:902 ||| JJ
failure  ||| S:902 E:910 ||| NN
was  ||| S:910 E:914 ||| VBD
achieved  ||| S:914 E:923 ||| VBN
in  ||| S:923 E:926 ||| IN
48 ||| S:926 E:928 ||| CD
%  ||| S:928 E:930 ||| NN
following  ||| S:930 E:940 ||| VBG
first  ||| S:940 E:946 ||| JJ
referral  ||| S:946 E:955 ||| NN
and  ||| S:955 E:959 ||| CC
57 ||| S:959 E:961 ||| CD
%  ||| S:961 E:963 ||| NN
following  ||| S:963 E:973 ||| VBG
subsequent  ||| S:973 E:984 ||| JJ
discussions  ||| S:984 E:996 ||| NNS
and  ||| S:996 E:1000 ||| CC
was  ||| S:1000 E:1004 ||| VBD
maintained  ||| S:1004 E:1015 ||| VBN
in  ||| S:1015 E:1018 ||| IN
95 ||| S:1018 E:1020 ||| CD
%  ||| S:1020 E:1022 ||| NN
of  ||| S:1022 E:1025 ||| IN
children  ||| S:1025 E:1034 ||| NNS
referred  ||| S:1034 E:1043 ||| VBD
for  ||| S:1043 E:1047 ||| IN
regimen  ||| S:1047 E:1055 ||| JJ
simplification ||| S:1055 E:1069 ||| NN
.  ||| S:1069 E:1071 ||| .
Following  ||| S:1071 E:1081 ||| VBG
advice ||| S:1081 E:1087 ||| NN
,  ||| S:1087 E:1089 ||| ,
dyslipidaemia  ||| S:1089 E:1103 ||| VBD
resolved  ||| S:1103 E:1112 ||| VBN
in  ||| S:1112 E:1115 ||| IN
42 ||| S:1115 E:1117 ||| CD
%  ||| S:1117 E:1119 ||| NN
and  ||| S:1119 E:1123 ||| CC
liver  ||| S:1123 E:1129 ||| JJ
function  ||| S:1129 E:1138 ||| NN
normalised  ||| S:1138 E:1149 ||| NN
in  ||| S:1149 E:1152 ||| IN
73 ||| S:1152 E:1154 ||| CD
%  ||| S:1154 E:1156 ||| NN
with  ||| S:1156 E:1161 ||| IN
biochemical  ||| S:1161 E:1173 ||| JJ
hepatitis ||| S:1173 E:1182 ||| NN
.  ||| S:1182 E:1184 ||| .
Adherence  ||| S:1184 E:1194 ||| RB
support  ||| S:1194 E:1202 ||| VB
aided  ||| S:1202 E:1208 ||| VBN
resolution  ||| S:1208 E:1219 ||| NN
of  ||| S:1219 E:1222 ||| IN
viraemia  ||| S:1222 E:1231 ||| NN
in  ||| S:1231 E:1234 ||| IN
nine  ||| S:1234 E:1239 ||| CD
children  ||| S:1239 E:1248 ||| NNS
and  ||| S:1248 E:1252 ||| CC
12 ||| S:1252 E:1254 ||| CD
%  ||| S:1254 E:1256 ||| NN
of  ||| S:1256 E:1259 ||| IN
referrals  ||| S:1259 E:1269 ||| NNS
resulted  ||| S:1269 E:1278 ||| VBD
in  ||| S:1278 E:1281 ||| IN
additional  ||| S:1281 E:1292 ||| JJ
support ||| S:1292 E:1299 ||| NN
,  ||| S:1299 E:1301 ||| ,
including  ||| S:1301 E:1311 ||| VBG
psychology ||| S:1311 E:1321 ||| NN
,  ||| S:1321 E:1323 ||| ,
social  ||| S:1323 E:1330 ||| JJ
services  ||| S:1330 E:1339 ||| NNS
and  ||| S:1339 E:1343 ||| CC
mental  ||| S:1343 E:1350 ||| JJ
health  ||| S:1350 E:1357 ||| NN
input ||| S:1357 E:1362 ||| NN
.  ||| S:1362 E:1364 ||| .
Combined  ||| S:1364 E:1373 ||| JJ
multidisciplinary  ||| S:1373 E:1391 ||| JJ
virtual  ||| S:1391 E:1399 ||| JJ
input  ||| S:1399 E:1405 ||| NN
with  ||| S:1405 E:1410 ||| IN
adult  ||| S:1410 E:1416 ||| NN
expertise  ||| S:1416 E:1426 ||| NN
in  ||| S:1426 E:1429 ||| IN
resistance  ||| S:1429 E:1440 ||| NN
and  ||| S:1440 E:1444 ||| CC
newer  ||| S:1444 E:1450 ||| JJR
agents ||| S:1450 E:1456 ||| NNS
,  ||| S:1456 E:1458 ||| ,
paediatric  ||| S:1458 E:1469 ||| JJ
knowledge  ||| S:1469 E:1479 ||| NN
of  ||| S:1479 E:1482 ||| IN
pill  ||| S:1482 E:1487 ||| NN
swallowing ||| S:1487 E:1497 ||| NN
,  ||| S:1497 E:1499 ||| ,
childhood  ||| S:1499 E:1509 ||| FW
formulations ||| S:1509 E:1521 ||| FW
/ ||| S:1521 E:1522 ||| FW
weight  ||| S:1522 E:1529 ||| FW
banding  ||| S:1529 E:1537 ||| FW
and  ||| S:1537 E:1541 ||| CC
parental  ||| S:1541 E:1550 ||| JJ
support ||| S:1550 E:1557 ||| NN
,  ||| S:1557 E:1559 ||| ,
assists  ||| S:1559 E:1567 ||| VBZ
complex  ||| S:1567 E:1575 ||| JJ
treatment  ||| S:1575 E:1585 ||| NN
decision  ||| S:1585 E:1594 ||| NN
making  ||| S:1594 E:1601 ||| VBG
in  ||| S:1601 E:1604 ||| IN
paediatric  ||| S:1604 E:1615 ||| JJ
HIV  ||| S:1615 E:1619 ||| NNP
infection ||| S:1619 E:1628 ||| NN
.  ||| S:1628 E:1630 ||| .
The  ||| S:1630 E:1634 ||| DT
Virtual  ||| S:1634 E:1642 ||| NNP
Clinic  ||| S:1642 E:1649 ||| NNP
model  ||| S:1649 E:1655 ||| NN
could  ||| S:1655 E:1661 ||| MD
be  ||| S:1661 E:1664 ||| VB
applied  ||| S:1664 E:1672 ||| VBN
to  ||| S:1672 E:1675 ||| TO
the  ||| S:1675 E:1679 ||| DT
management  ||| S:1679 E:1690 ||| NN
of  ||| S:1690 E:1693 ||| IN
other  ||| S:1693 E:1699 ||| JJ
rare  ||| S:1699 E:1704 ||| JJ
complex  ||| S:1704 E:1712 ||| JJ
diseases  ||| S:1712 E:1721 ||| NNS
of  ||| S:1721 E:1724 ||| IN
childhood  ||| S:1724 E:1734 ||| NN
within  ||| S:1734 E:1741 ||| IN
a  ||| S:1741 E:1743 ||| DT
clinical  ||| S:1743 E:1752 ||| JJ
network ||| S:1752 E:1759 ||| NN
.  ||| S:1759 E:1761 ||| .
